Clinical Trial Update: Pyrimethamine and Sulfadoxine for Treatment of Autoimmune Lymphoproliferative Syndrome [Phase 1]

View source ↗

Summary

Phase 1 trial evaluating a pyrimethamine and sulfadoxine combination for autoimmune lymphoproliferative syndrome has completed, sponsored by NIAID.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Autoimmune Lymphoproliferative Syndrome

Drugs mentioned

• Pyrimethamine (Pyrimethamine)
• Sulfadoxine (Sulfadoxine)

Snippet

Sponsor: National Institute of Allergy and Infectious Diseases (NIAID) | Conditions: Autoimmune Disease, Lymphoproliferative Disorder | Phase 1 | Status: COMPLETED